1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 9, 2, 22, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gouty Arthritis (Gout) - Overview
- Gouty Arthritis (Gout) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gouty Arthritis (Gout) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
- Gouty Arthritis (Gout) - Drug Profiles
- Gouty Arthritis (Gout) - Dormant Projects
- Gouty Arthritis (Gout) - Discontinued Products
- Gouty Arthritis (Gout) - Product Development Milestones
- Featured News & Press Releases
- Aug 09, 2022: Arthrosi completes AR882 renal impairment study
- Aug 03, 2022: LG Chem enters final stage of clinical development for new gout drug
- Jul 19, 2022: Allena pharmaceuticals announces completion of enrollment of cohorts A and B of ALLN-346 phase 2a study 202 in patients with Gout and stages 2 and 3 chronic kidney disease
- Jun 16, 2022: Atom Bioscience to update clinical development of new drug to treat gout at BIO International Convention, June 13 - 16, 2022, San Diego, CA
- Jun 13, 2022: Selecta Biosciences announces partnership advancements and clinical trial updates
- Jun 02, 2022: Dyve Biosciences announces phase 2 TARGETS study of DYV702 for pain associated with acute gout flares showcased in podium presentation at 2022 EULAR congress
- May 31, 2022: Fortress Biotech announces first patient dosed in phase 1 clinical trial evaluating dotinurad for the treatment of gout in the United States
- Mar 21, 2022: Atom Bioscience announces positive phase 2a results for investigational new drug to treat chronic gout
- Mar 15, 2022: The Phase I clinical trial of Eusen Jianheng's new gout drug UA007 was successfully completed
- Dec 14, 2021: Arthrosi Therapeutics announces patient enrollment in global phase 2b study of AR882
- Dec 02, 2021: Sobi and Selecta Biosciences complete enrolment for gout therapy trial
- Nov 15, 2021: Dyve Biosciences hosting key opinion leader webinar on Gout and DYV702
- Nov 08, 2021: Shanghai Fosun Pharmaceutical (Group) announcement in relation to the approval for Clinical Trial regarding Investigational New Drug of a subsidiary
- Nov 03, 2021: Allena Pharmaceuticals receives Fast Track Designation from FDA for the Development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease
- Nov 02, 2021: Arthrosi presents AR882 posters at ACR 2021
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Gouty Arthritis (Gout), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gouty Arthritis (Gout) - Dormant Projects, 2022
- Gouty Arthritis (Gout) - Discontinued Products, 2022
- Number of Products under Development for Gouty Arthritis (Gout), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Aclaris Therapeutics Inc
- Acquist Theraputics Inc
- Akaal Pharma Pty Ltd
- Allena Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Aqilion AB
- Arrowhead Pharmaceuticals Inc
- Arthrosi Therapeutics Inc
- C&C Research Laboratories
- Deep Genomics Inc
- DevaCell Inc
- Dianomi Therapeutics Inc
- Dyve Biosciences Inc
- Enzychem Lifesciences Corp
- EryDel SpA
- Fochon Pharmaceutical Ltd
- FortuneRock (China) Ltd
- Fuji Yakuhin Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Hangzhou Grand Biologic Pharmaceutical Inc
- Hinova Pharmaceuticals Co Ltd
- Horizon Therapeutics Plc
- IcanoMAB GmbH
- InflammatoRx inc
- InventisBio Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- LG Chem Ltd
- Nippon Chemiphar Co Ltd
- Olatec Therapeutics LLC
- PegBio Co Ltd
- Polaris Pharmaceuticals Inc
- Protalix BioTherapeutics Inc
- Rigel Pharmaceuticals Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shanton Pharma Co Ltd
- Stealth Biologics LLC
- Synlogic Inc
- TaiwanJ Pharmaceuticals Co Ltd
- Teijin Pharma Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- TWi Biotechnology Inc
- Usynova Pharmaceuticals Ltd
- Wellstat Therapeutics Corp
- West Lake Biomedical Technology (Hangzhou) Co Ltd
